



Supplementary Figure 1. Kaplan-Meier survival curve for AT-rich interactive domain 1A (ARID1A) according to the luminal B, human epidermal growth factor receptor 2 (HER2), and triple-negative breast cancer (TNBC) subtype. (A) Disease-free survival ($p=0.874$) and (B) overall survival ($p=0.313$) in patients with in luminal B, HER2 negative type (n=76). (C) Disease-free survival ($p=0.238$) and (D) overall survival ($p=0.067$) in patients with in luminal B, HER2 positive type (n=37). (E) Disease-free survival ($p=0.016$) and (F) overall survival ($p=0.087$) in patients with in HER2 type (n=46). (G) Disease-free survival ($p=0.144$) and (H) overall survival ($p=0.114$) in patients with in TNBC basal type (n=81). (I) Disease-free survival ($p=0.258$) and (J) overall survival ($p=0.408$) in patients with in TNBC nonbasal type (n=31).